Crinetics Pharmaceuticals, Inc. (CRNX)
| Market Cap | 4.42B +51.1% |
| Revenue (ttm) | 18.07M +2,277.5% |
| Net Income | -496.39M |
| EPS | -5.13 |
| Shares Out | 105.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,380,621 |
| Open | 40.00 |
| Previous Close | 38.68 |
| Day's Range | 39.83 - 42.30 |
| 52-Week Range | 25.83 - 57.99 |
| Beta | 0.23 |
| Analysts | Strong Buy |
| Price Target | 83.14 (+98.52%) |
| Earnings Date | Aug 4, 2026 |
About CRNX
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candida... [Read more]
Financial Performance
In 2025, Crinetics Pharmaceuticals's revenue was $7.70 million, an increase of 640.71% compared to the previous year's $1.04 million. Losses were -$465.32 million, 55.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for CRNX stock is "Strong Buy." The 12-month stock price target is $83.14, which is an increase of 98.52% from the latest price.
News
Crinetics initiated with a Buy at UBS
UBS analyst Ashwani Verma initiated coverage of Crinetics (CRNX) with a Buy rating and $55 price target The stock’s 44% pullback since mid-January provides an attractive entry point, the analyst…
Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 after t...
Crinetics Pharmaceuticals Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation approval. All proposals passed, and no questions were raised by stockholders during the Q&A session.
Crinetics presents full results from Phase 2 trial of atumelnant
Crinetics (CRNX) Pharmaceuticals presented data from the open-label, Phase 2 congenital adrenal hyperplasia adult study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic horm...
Crinetics presents long-term data from program evaluating Palsonify
Crinetics (CRNX) Pharmaceuticals announced new long-term data from its clinical development program evaluating novel Palsonify in acromegaly during an oral presentation at the Endocrine Society’s Annu...
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms
Leerink sees favorable readthrough to Crinetics after Camurus’ Oclaiz CRL
Leerink analyst Joseph Schwartz notes that Camurus received a complete response letter for Oclaiz in acromegaly. The firm sees positive readthrough to Crinetics (CRNX), as the CRL at least delays…
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy' Initiative to Empower People Across Endocrine Disease Communities
Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions
Crinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taki...
Crinetics price target lowered to $88 from $89 at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on Crinetics (CRNX) to $88 from $89 and keeps an Outperform rating on the shares.
Crinetics price target lowered to $84 from $87 at Oppenheimer
Oppenheimer lowered the firm’s price target on Crinetics (CRNX) to $84 from $87 and keeps an Outperform rating on the shares following quarterly results. Phase 3 trial in carcinoid syndrome…
Crinetics price target lowered to $95 from $97 at Citizens
Citizens lowered the firm’s price target on Crinetics (CRNX) to $95 from $97 and keeps an Outperform rating on the shares. Palsonify’s launch appears strong with expanding prescriber adoption and…
Crinetics Pharmaceuticals Earnings Call Transcript: Q1 2026
PALSONIFY’s Q1 2026 launch drove $10.3M in net product revenue and 232 new enrollments, with strong adoption across patient types and 70% reimbursement. The company maintains robust cash reserves, advances a deep pipeline, and expects to exceed 75% coverage by Q3.
Crinetics Pharmaceuticals Earnings release: Q1 2026
Crinetics Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Crinetics Pharmaceuticals Quarterly report: Q1 2026
Crinetics Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Crinetics Pharmaceuticals Slides: Q1 2026
Crinetics Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter Management Hosting Conference Call at 4:30 p.m. ET Today ...
Crinetics Pharmaceuticals Proxy statement: Proxy filing
Crinetics Pharmaceuticals filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Crinetics Pharmaceuticals Proxy statement: Proxy filing
Crinetics Pharmaceuticals filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Crinetics price target raised to $97 from $96 at Citizens
Citizens analyst Jonathan Wolleben raised the firm’s price target on Crinetics (CRNX) to $97 from $96 and keeps an Outperform rating on the shares. Palsonify has been approved across the…
Crinetics’ Palsonify approved by European Commission for acromegaly
Crinetics (CRNX) announced that the European Commission has approved Palsonify – paltusotine -, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for th...
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medica...
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after the...
Crinetics submits Palsonify marketing authorization application to ANVISA
Crinetics (CRNX) announced the submission of a marketing authorization application to Brazil’s National Health Surveillance Agency, or ANVISA, for Palsonify, the first once-daily, oral, selectively-ta...